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ABSTRACT 
 
Rift Valley fever virus (RVFV) is an emerging zoonotic pathogen that has been responsible for 
extensive and devastating outbreaks of disease in both humans and livestock throughout Africa 
and the Arabian Peninsula.  Humans infected with RVFV can recover after a brief febrile illness 
or go on to develop a more severe outcome including encephalitis, hepatitis, or hemorrhagic 
fever.  Although human transmission primarily occurs through direct interaction with sick 
animals, inhalational infection can occur, making aerosolized RVFV a plausible bioweapon with 
potential for severe public health consequences.  RVFV does not have a well-characterized rat or 
non-human primate (NHP) model for aerosol challenge. Animal models are essential for the 
testing of medical countermeasures, with knowledge of the host immune response aiding in their 
development.  To further our understanding of the role that antibodies play in shaping the 
outcome of respiratory disease, inbred rats and non-human primates were exposed to aerosolized 
RVFV.  Wistar-Furth, ACI, and Lewis rats were challenged in median lethal dose and serial 
sacrifice studies from which samples were tested to determine the robustness and timing of the 
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IgG response. Wistar-Furth rats succumbed to hepatic disease shortly after infection, and never 
mounted a detectable antibody response.  ACI and Lewis rats developed neurologic disease, with 
IgG appearing 6 d.p.i. and potentially influencing host survivability.  To investigate the 
significance of the humoral response during respiratory infection of NHPs, cynomolgus 
macaques, rhesus macaques, African Green monkeys, and marmosets, were inoculated with 
RVFV via aerosol route, with blood samples taken at several time points. Cynomolgus and 
rhesus species were not sensitive to developing disease, but elicited strong IgG and neutralizing 
antibodies in response to inoculation. AGMs and marmosets showed moderate to high 
susceptibility to neurologic disease, even in the presence of extremely high titers of neutralizing 
antibodies.  Further immunity studies are pertinent to better comprehend these host-pathogen 
interactions after RVFV aerosol challenge. 
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1.0  INTRODUCTION 
Rift valley fever virus (RVFV) is an enveloped, single-stranded RNA virus of the 
Bunyaviridae family and Phlebovirus genus1.  Its segmented genome is approximately 11.9 
kilobases in length2, in which two segments (L and M) are negative sense, and the other segment 
(S) is ambisense3.  The virus encodes 6 proteins: the viral RNA polymerase (L segment), the Gn 
and Gc glycoproteins (M segment), NSm (M segment), NSs (S segment, complementary 
orientation), and the nucleoprotein (S segment, antisense orientation)4.  
RVFV is zoonotic pathogen that infects both animals and humans and is transmitted 
primarily by mosquitoes5.  Ruminants are most susceptible to infection, with epizootics 
characterized by abortion storms and neonatal mortality nearing 100%6.  The adult livestock 
mortality rate is approximately 10-20%7.  Humans can be infected with the virus through a bite 
from an infected mosquito or by percutaneous or aerosol routes following exposure to infected 
animal tissue8.  Although most humans get a self-limited febrile illness, 1-2% of those infected 
will develop severe disease with the case fatality rate of the affected persons being 
approximately 10 to 20%910. 
Although outbreaks have occurred only in Africa and the Arabian Peninsula11, the virus 
can utilize dozens of mosquito species that are present in North America and Europe12.  The 
virus could be introduced to virgin soil accidentally by international travel or importation of 
infected animals and mosquitoes, or deliberately through acts of bioterrorism.  The CDC, USDA, 
and WHO consider RVFV to be a major zoonotic threat due to its potential for severe 
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consequences and international spread13.  The result of an outbreak on virgin soil could cause 
significant direct and indirect consequences for the affected areas.   
1.1 RIFT VALLEY FEVER VIRUS 
1.1.1 Epidemiology and transmission 
Rift Valley fever virus was first reported by veterinarians and livestock officers in the 
early 1900s14, but it wasn’t until 1931 that the virus was isolated during an outbreak in lambs and 
ewes in the Great Rift Valley of Kenya15.  Since then, the virus has been responsible for 
devastating epidemics in regions of Africa, including Kenya16, Tanzania17, Sudan18, Egypt19, and 
Mauritania20, and more recently, Yemen21 and Saudi Arabia22.   
RVFV is most commonly found in areas where livestock is raised, such as eastern and 
southern Africa, but the virus also exists in most sub-Saharan countries, as well as Madagascar23.  
The first outbreak that occurred outside of Africa was reported in 2000 in the Arabian 
Peninsula24. 
Multiple human disease outbreaks have occurred in the past several decades.  An 
epidemic in 1977 in Egypt caused approximately 18,000 cases of disease and resulted in nearly 
600 deaths25.  An outbreak in Senegal-Mauritania in 1987 caused infection in 89,000 individuals, 
with more than 200 deaths reported26. Sudan experienced an outbreak in 2007, with a total of 
747 laboratory confirmed cases and 230 recorded deaths.  The total number of human cases 
during the Sudan outbreak is estimated to be close to 75,00027, but due to the poor health 
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infrastructure in rural areas, many cases of RVFV infection go unreported, as many people never 
seek medical attention for an accurate diagnosis28.   
RVFV primarily infects livestock including sheep, cattle, buffalo, camels, and goats, but 
is also capable of infecting dogs, cats, horses, monkeys, rodents, and humans29.  Virus 
amplification occurs primarily in sheep and cattle30.  The virus is incredibly pathogenic in 
livestock, with the most notable livestock outbreak occurring in Kenya in 1950-1951, which 
resulted in the death of 100,000 sheep and 500,000 abortions31.  Neonatal and fetal mortality can 
reach nearly 100%, as the virus is known to be transmitted in utero.  In 2006, the first report of in 
utero transmission to a human fetus was described32.   
The main route of transmission for livestock is through a variety of mosquito vectors, 
specifically Aedes, Culex, and Anopheles species33.  The virus has been isolated in over 40 
mosquito species, in 8 genera34.  Several of the susceptible vectors are present in Europe and 
North America, making international expansion of the virus a serious concern.  Florida has been 
suggested as an optimal location for the virus to inhibit due to its tropical and sub-tropical 
regions and capable mosquito vectors35.   
Epizootics of Rift Valley fever typically occur during years of excessive rainfall and 
flooding.  The virus can lay dormant in competent mosquito reservoirs during inter-epidemic 
periods, but large amounts of rainfall cause explosive hatching of infected mosquito eggs.  The 
mosquitoes then feed on livestock, transferring and amplifying the virus, causing the disease to 
spread36.  Humans are primarily infected through contact with sick livestock, but can also 
contract the disease through mosquito bites or through aerosol exposure to blood, body fluids, or 
tissues from infected animals37.  Slaughterhouse workers and those handling sick animals are 
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most at risk for infection during outbreaks, and make up the majority of inhalational Rift Valley 
Fever cases38.  Accidental laboratory aerosol exposures have been reported a number of times39. 
1.1.2 Pathogenesis 
Similar to all bunyaviruses, with the exception of those in the Hantavirus genus, Rift 
Valley fever virus replicates in arthropods40.  The mosquito’s gut initially becomes infected and 
virus becomes detectable in the saliva after several days or weeks. When the vector feasts on the 
blood meal of a vertebrate, their viremic saliva enters into the lymphatic system or capillaries of 
the host.  The primary site of replication has yet to be elucidated, but the most probable sites are 
the regional lymph nodes41.   
The virus has a broad tropism and is known to infect peripheral blood mononuclear cells 
(PBMCs), including monocytes and macrophages, lymphocytes, and dendritic cells.  RVFV can 
also target other organs, such as the liver and brain42.  Although full characterization of cell 
surface attachment factors has not been determined, heparin sulfate has been implicated in 
facilitating attachment and entry into cells43.   
RVFV epizootics are typically characterized by sweeping abortion storms ruminants, 
with nearly 100% of pregnant animals miscarrying.  Loss of the fetus is characterized by 
cytokine storms, multiple organ infection, and fetal necrosis.  Neonatal sheep that are less than 
one month old are also extremely susceptible to infection.  After a short incubation period of 12 
to 24 hours, a marked fever develops in the animal with progression to death occurring within 24 
to 72 hours post-infection due to necrotic hepatitis44.  Ninety to 100% of sheep neonates 
succumb to clinical disease.  Neonatal calves are less susceptible to RVFV infection, but disease 
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course is similar and mortality estimates still range from 10-70%.  Adult livestock are more 
resistant to the virus, but death still occurs in 10-30% and 5-10% of infected sheep and cattle, 
respectively.  Symptoms of Rift Valley fever include fever, lethargy, anorexia, diarrhea, and 
nasal discharge.  In highly susceptible animals, death results from hemorrhage and hepatitis45. 
In humans, the spectrum of disease ranges from mild or inapparent to severe outcomes 
that result in death.  The incubation period ranges from 2 to 6 days, typically followed by a self-
limiting illness characterized by fever, anorexia, myalgia, headache, and gastrointestinal distress. 
For the majority of cases, the disease fully resolves itself in several weeks with no sequelae. 
However, in a small percentage of those infected (1-2%), the infection can progress to more 
severe clinical disease including hemorrhagic fever, acute hepatitis, encephalitis, and retinitis 
leading to blindness.  In those most severely affected, coagulopathy, multiple organ dysfunction, 
renal and hepatic failure, and meningoencephilitis precipitate death.  Approximately 10-20% of 
those with a severe infection will have a fatal outcome.  The mechanisms of pathogenesis that 
determine clinical disease outcome are not fully understood and are still under investigation46. 
1.1.3 Host immune response 
Detailed studies of the immune response elicited by RVFV infection are severely lacking. 
Due to the inadequacy of infrastructure and resources in many endemic countries and the 
absence of well-characterized animal models, research has been limited.  Like most ssRNA 
viruses, RVFV encodes virulence factors to defend against the immune system by inhibiting the 
actions of type I interferon47 and deregulating a broad spectrum of cytokines48.  
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Although innate components of immunity have undergone cursory investigation, 
information on the humoral response during severe infection is extremely sparse.  It is 
understood that neutralizing antibodies are directed at the viral glycoproteins, Gn and Gc, and 
that high titers are thought to mediate initial and persistent protection against disease49.  Studies 
using passive antibody transfer have proven inconclusive63.  Binding antibodies are targeted 
against the N protein, the dominant immunogen in bunyavirus infection50, and are responsible 
for promoting complement fixation51.  Antibodies are also raised against the non-structural NSs 
protein, but to a lesser degree.  It is relatively unknown what responsibilities these antibodies 
play in influencing clinical outcome.  Huge gaps exist in our knowledge of the humoral immune 
response to RVFV, and further examination of all aspects of immunity is needed. 
1.1.4 Prevention and Treatment 
At this time, no licensed vaccines52 or therapeutics53 exist for Rift Valley fever virus. 
Several live-attenuated strains of Rift have been tested for their prophylactic efficacy, all of 
which conferred varying degrees of protection and possessed specific limitations. 
The first vaccine created, known as the Smithburn strain, was adapted by serial passaging 
of virulent RVFV in mouse brain. It induced abortions and teratogenesis in livestock and was 
reserved for use with non-pregnant animals only during devastating outbreaks.  Since then, a 
formalin-inactivated Smithburn vaccine has been produced, but is not as efficacious as its live-
attenuated counterpart and requires several boosters.  Reversion to virulence is a risk for the 
mouse-adapted strain54. 
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In response to the 1977 Egyptian outbreak, USAMRIID developed a vaccine strain by 
passaging the virulent ZH548 strain 12 times in the presence of 5-fluorouracil to induce 
mutagenesis55.  This strain was designated MP-12, and contained mutations in all 3 genome 
segments56.  The vaccine initially showed promise in evoking immunogenicity to RVFV, but 
after a trial in South Africa, it was revealed that MP-12 could induce abortion and teratogenesis 
during early pregnancy in sheep.  Despite this setback, MP-12 is still being pursued for human 
and veterinary prophylaxis57. 
The last existing vaccine is Clone 13, an isolate of RVFV found to contain a large 
deletion in the coding region for the NSs protein, the major virulence factor of RVFV58.  This 
deletion makes it impossible for the virus to revert to wildtype, and trials in multiple species of 
livestock have shown impressive antibody responses.  Importantly, immunization did not induce 
abortion in pregnant animals, nor did it result in negative side effects59.  Although none of the 
vaccines are FDA approved, some countries still utilize them to inoculate livestock during 
periods of outbreak60.  
No therapeutics exist for established RVFV infection, other than palliative care61.  
Ribavirin has been tested as an antiviral treatment for experimentally-infected animals with 
minimal success.  The compound does not efficiently cross the blood-brain barrier and would be 
of limited use in preventing delayed-onset encephalitis.  Astonishingly, RVFV-infected 
laboratory animals receiving ribavirin treatment were associated with a pronounced shift in 
disease characteristics from acute hepatitis to neurological disease and hence, the drug is not 
recommended for those suffering from mild cases of disease62. Alternative treatments such as 
interferon and passive antibody therapy have been pursued, but efficacy from these clinical trials 
has proven to be inconclusive63. 
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1.2 PUBLIC HEALTH SIGNIFICANCE OF RVFV INFECTION 
Due to the potential for severe consequences during disease outbreaks, Rift Valley fever 
virus is classified as a category A overlap select agent by the Centers for Disease Control and 
Prevention (CDC), the National Institute for Allergy and Infectious Diseases (NIAID), and the 
USDA.  It is also categorized as a high-consequence pathogen with the potential for international 
spread (List A) by the World Health Organization (WHO) for Animal Health64.  Because of this, 
RVFV is considered a potential bioterror agent that could have dramatic direct and indirect 
impact in countries that are currently free of the virus.  Due to the increase in international travel 
and trade in the past decades, transmitting RVFV into naïve regions through these means is also 
highly feasible65. 
1.2.1 Biological warfare 
Intentional exposure to Rift Valley fever virus through bioterrorism is a definite 
possibility, especially due to certain viral characteristics.  The selection of viruses for use as 
bioweapons depends on several factors: the relative infectivity in the target populations, the 
ability to induce a fatal or incapacitating illness, the ease of propagating large amounts of high 
titer stock in cell culture, the competency to be transmitted via aerosol, and the dearth of 
measures available to control the virus.  Several viruses in the Bunyaviridae and Togaviridae 
families have been cited as potentially important bioterrorism weapons, with Rift Valley fever 
virus holding the highest priority66. 
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RVFV was heavily researched during the Cold War for use as a weaponized aerosol.  The 
aerosol form proved to be very stable, and could facilitate infection through inhalation.   At room 
temperature with 30% relative humidity, RVFV was found to have a half-life of 77 minutes 
when in aerosol form67.  During an assessment of the possible damage that a bioterrorist attack 
with RVFV could cause, consultants from WHO calculated that if 50 kg of virus was released 
from an aircraft in the center of a population of 500,000 persons, an estimated 35,000 people 
would be incapacitated and 400 deaths could occur68.  In epidemic regions human infection rates 
can reach as high as 35%, as seen from previous outbreaks69.  Aside from the direct impact on 
the population, susceptible livestock could be infected and endemic disease could be established 
in the area70.   
1.2.2 Importation of virus to virgin territories. 
As seen with the rapid spread of West Nile virus after its introduction to North America 
in 1999, there is high potential for foreign viruses to become easily established in the United 
States.  Globalization of commerce and travel has provided likely routes for arbovirus 
establishment, with high-temperature areas, dense regions of livestock, and places with a bounty 
of capable mosquito vectors being the most probable regions for the virus to lay its foundation. 
Although human infection is an immense concern, it has been estimated that the livestock 
industry could lose billions of dollars due to death of animals and imposed trade restrictions if an 
outbreak RVFV were to occur in the USA, having severe socio-economic impact on our 
country71. 
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While investigating the potential for RVFV to enter the United States, a pathways 
analysis revealed that one of the most likely routes of entry is through infected persons or 
mosquitos arriving by airplane into the country. It was found that over 97% of individuals 
travelling to the USA from RVFV-endemic countries arrived at airports in one of six population-
dense locations: New York City, Washington DC, Atlanta, Baltimore, Newark, and Houston72.  
These areas, as well as several other states, have been identified as particularly vulnerable 
regions to RVFV exposure.   
Other factors come into play for the importation of virus, such as the unknown impact 
that global warming could have on arbovirus spread73. 
1.3 RVFV ANIMAL MODELS 
Animal models are invaluable tools for biomedical research.  The models allow for the 
study of disease pathogenesis, as well as for evaluation of potential prophylaxis and treatment, 
when human clinical trials are not possible.   
Several models including sheep, hamsters, mice, rats, and non-human primates have been 
used for experimental infections and pathogenesis studies.  Choosing the most relevant animal 
model is based on many factors such as the virus strain, inoculation route and dose, animal age 
and species, and pathology that is similar to that seen in the natural host.   Despite vigorous 
research efforts, a well-characterized animal model for aerosolized RVFV pathogenesis has not 
yet been established.   
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1.3.1 Rats 
A study conducted in 1982 by Peters and Sloan revealed that disease outcome was 
dependent on the strain of inbred rat when inoculated subcutaneously.  Wistar-Furth rats became 
systemically viremic and all succumbed within a few days to acute hepatitis after exposure to the 
ZH501 strain of RVFV.  August Copenhagan Irish (ACI) rats were moderately susceptible to 
RVFV subcutaneous (s.c.) infection, with half of the rats expiring after displaying neurological 
symptoms and mimicking the encephalitic disease seen in humans.  Lewis rats displayed no 
clinical disease after s.c. exposure to ZH501 but had detectable viremia and antibody responses, 
indicating that they were not resistant to infection, but were able to sufficiently control it74.   
The Hartman lab is actively working to establish a rat model for aerosol infection of 
RVFV, using the ZH501 strain.  Similar to the results seen by Peters and Sloan, Wistar-Furth and 
ACI rats exposed to aerosolized RVFV exhibited extensive hepatic disease and 
meningoencephilitis, respectively.  Mortality rates were 100% for both rat strains when exposed 
to extremely lose doses of virus, many folds lower than those used in the Peters and Sloan 
studies.  Surprisingly, Lewis rats were not able to efficiently control respiratory infection, and 
developed lethal neurological disease like that of the ACI rats.  Lewis rats were also inoculated 
s.c., and later re-challenged via aerosol with the identical virus strain to determine if the s.c.
infection protected them against aerosol infection.  It was found that the prior infection offered 
no safeguard against aerosol challenge75, suggesting possible implications for the development 
and efficacy of vaccines and therapeutics to protect against respiratory exposure.   
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1.3.2 Non-human primates 
Non-human primates (NHPs) are often the most desired animal model when investigating 
human disease due to similarities in clinical illness.  Unlike inbred rat strains, studies with non-
human primates have shown more variability in the clinical outcome after RVFV infection.  The 
first NHP study in 1931 described an infection of rhesus macaques that induced a fever response 
with leukopenia, but did not cause severe disease and death.  Different routes of inoculation, 
such as intraperitoneal (i.p.), intracerebral (i.c.), s.c, and intranasal (i.n.), were attempted to 
induce a fatal infection, but no clinical symptoms developed.  Other studies have found that 
rhesus macaques and cynomolgus macaques are more susceptible to aerosol RVFV exposure, but 
low levels of morbitity still persisted76.   
Although rhesus macaques dependably mimic the spectrum of disease seen in humans, 
studies have shown that less than 20% of the animals develop fatal disease, which is not ideal for 
the testing and development of pharmaceuticals.  Other NHP studies have employed South 
American capuchins and marmosets as models for infection and found their susceptibility to be 
slightly higher than other NHP species77.   
Several laboratories are working on the development of a susceptible NHP model that 
imitates the severe outcomes of human infection including acute hepatitis, delayed-onset 
encephalitis, and hemorrhagic syndrome.  At this time, it appears that the New World common 
marmoset may represent the most realistic model of the severe clinical outcomes seen in humans.  
A recent study found the mortality rate for marmosets to range from 25-100%, depending on the 
route of exposure, with 50-100% of the NHPs displaying clinical symptoms of infection. 
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Interestingly, marmosets that were inoculated intranasally had the highest rates of morbidity and 
mortality78.   
Given that aerosol exposure has occurred in laboratory and epidemic settings and is the 
most likely route of exposure if a bioterrorist attack were to occur, the Hartman lab is currently 
investigating the pathogenesis of respiratory infection in non-human primates.   
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2.0  STATEMENT OF THE PROJECT AND SPECIFIC AIMS 
Defining an animal model includes characterizing the immune response to the delivered 
pathogen.  The humoral response plays an important role in clearing infections and affecting the 
pathogenesis of the disease.  The goal of this project is to elucidate the total IgG antibody 
response for the aerosolized rat strains and the total IgG and neutralizing antibody response for 
the aerosolized non-human primate species that mimic severe clinical manifestations in humans. 
Determining if the antibody response is responsible for protecting against fatal infection will 
give insight into possible mechanisms for developing prophylaxis and treatment.  Our working 
hypothesis is that the humoral response elicited by aerosolized Rift Valley fever virus helps 
determine the disease outcome for the animal models.  This hypothesis will be tested with the 
following specific aims. 
Aim 1: To develop methodology for measuring antibody responses using an indirect IgG 
enzyme-linked immunosorbant assay (ELISA) and plaque reduction neutralization test 
(PRNT50) for quantitative determination of antibodies in 3 strains of rats and 4 species of 
non-human primates exposed to aerosolized Rift Valley fever virus.  To address this aim, 
indirect IgG ELISA and PRNT50 protocols were optimized for sensitivity and specificity for use 
with rat and non-human primate serum samples.  The ELISA assay measured the total amount of 
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RVFV-specific IgG present in the serum of both rats and non-human primates.  The PRNT50 
assay determined the titer of virus-specific neutralizing antibodies present in rat and non-human 
primate serum.   
Aim 2: To characterize the strength and timing of the total IgG antibody response in the 3 
rat strains exposed to aerosolized RVFV.   Total IgG antibody titers in rat serum were 
quantitated by indirect ELISA using a sumOD approach.  Results were compared between the 
rats that survived aerosol challenge and those that succumbed to disease.  For serial sacrifice 
studies, the timing of the total IgG antibody response was determined by indirect ELISA using 
the sumOD approach. 
Aim 3:  To characterize the strength and timing of both the total IgG and neutralizing 
antibody responses in 4 species of non-human primate exposed to aerosolized RVFV.  Total 
IgG antibody titers were quantitated in non-human primates by indirect ELISA using a sumOD 
approach.  Results were compared between monkeys that survived aerosol exposure and those 
that succumbed to disease.  Neutralizing antibody titers were measured by a plaque-reduction 
neutralization test (PRNT50) in non-human primate serum samples at various time points to 
determine their importance in clinical outcome.  Pre-infection, intermediate, and endpoint 
samples were compared between animals, if available. 
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3.0  MATERIALS AND METHODS 
3.1 BIOSAFETY 
All experiments using live ZH501 RVFV were performed in the biosafety level 3+ 
Regional Biocontainment Laboratory (RBL) at the University of Pittsburgh.  Powered air 
purifying respirators (PAPRs) were worn for respiratory protection and all work was conducted 
in a class II biosafety cabinet using Vesphene IIse (diluted 1:128, Steris Corporation, cat. 
#646101) as a disinfectant.  Work involving MP-12 RVFV was performed under BSL-2 
conditions in a class II biosafety cabinet, using Vesphene IIse (1:128) 
3.2 CELL CULTURE 
Vero E6 and BHK-21 cells (ATCC) were cultured in Dulbecco’s Modified Eagle 
Medium supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 1% L-
glutamine (complete DMEM).  Cells were split upon reaching confluency using 0.05% 
trypsin/EDTA.  Cultured cells were maintained in a humidified incubator (37oC, 5% CO2).  
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3.3 GENERATION OF LYSATES 
BHK-21 cells were seeded into 4 T-150 flasks using complete DMEM until confluent. 
Media was removed from confluent flasks.  Two flasks received an inoculum of complete 
DMEM (mock-infected) and two flasks received MP-12 RVFV (kind gift from T. Ross), at an 
MOI of 0.1. The infected flasks were incubated for 1 hour at 37OC, 5% CO2 with gentle rocking 
every 15 minutes.  After incubation, the inoculum was removed from the flasks and the cells 
were washed briefly with DPBS.  Thirty mL of Opti-MEM (reduced serum media) supplemented 
with 1% pen/strep was added to all flasks.  The infected flasks were incubated for 2 days and 
then moved overnight into a -80oC freezer after marked cytopathic effects (CPE) were seen.  The 
flasks were then removed from the freezer and placed back into the incubator to quickly thaw 
and lyse the cells.  After the freeze-thaw cycle, the infected media was centrifuged at 1000 RPM 
for 10 minutes at 24oC.  Lysate was collected and corresponding mock- and MP-12-infected 
flasks were combined together.  A small aliquot from the MP-12-infected flasks was saved for 
plaque assay titer confirmation.  All remaining lysate was inactivated with 0.1% β-propriolactone 
for 24 hours before moving to the -80oC freezer.   
3.4 PLAQUE ASSAY 
Vero E6 cells suspended in complete DMEM were seeded into 6-well plates overnight 
until 95% confluent.  Serial dilutions of the sample lysate were prepared in DMEM 
supplemented with 2% FBS.  Media was removed from the cells and 200 µl of the diluted lysate 
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was added to the wells in duplicate.  Plates were incubated for 1 hour with gentle rocking every 
15 minutes.  After incubation, the inoculum was removed from the wells and nutrient overlay 
(1X minimum essential medium, 2% FBS, 1% pen/strep, HEPES buffer, and 0.8% SeaKem 
agarose) was added.  After the overlay solidified, the plates were allowed to incubate for 3 days 
at 37oC, 5% CO2.  After formation of plaques, 37% formaldehyde was added to the wells and 
allowed to fix in the biosafety cabinet for several hours.  Formaldehyde was drained from the 
plates and disposed of appropriately, and the agar plugs were removed from the wells.  Crystal 
violet working solution (diluted in 35% ethanol) was then added to the plates to visualize the 
plaques and determine a titer. 
3.5 INDIRECT IGG ELISA 
Immulon 2HB 96-well plates (Fisher Scientific, cat. #14-245-61) were coated with 100 µl 
of mock-infected or MP-12-infected inactivated lysate (diluted 1:20 in DPBS) and incubated 
overnight at 4oC.  After washing the plates 3 times with PBS-T (1X PBS + 0.05% Tween, Fluka, 
cat. #08057-12TAB-F), 200 µL of blocking buffer (PBS-T + 5% blotting grade blocker, Bio-
Rad, cat. #170-6404XTU) was added to the wells and allowed to incubate for 1 hour at 37oC, 5% 
CO2.  Plates were washed 3 times as before, and 100 µL of control or test sera (diluted 1:100-
1:6400, four-fold, in blocking buffer) was added in duplicate to the wells.  The plates were 
incubated at 37oC for 1 hour.  Plates were washed 3 times, followed by the addition of 100 uL of 
horseradish peroxidase-conjugated goat anti-rat IgG (H+L, KPL, cat. #14-16-06) or goat anti-
monkey IgG (γ, KPL, cat. #074-11-021), diluted 1:4000 in blocking buffer.  The secondary 
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antibody was incubated for 1 hour at 37oC, washed 3 times, and 100 µL of 2,2’-
azinodiethylbenzothiazoline sulfonic acid (ABTS) substrate (KPL, cat. # 50-66-18) was added to 
each well.  Plates were incubated in the dark at 37oC for 30 minutes.  After that time, 100 µL of 
ABTS stop solution (1% sodium dodecyl sulfate, KPL, cat. #50-85-01) was added to the wells 
and the optical density (OD) was determined at 405 nm.   
3.6 PLAQUE REDUCTION NEUTRALIZATION TEST 
Sera samples to be tested were heat inactivated at 56oC for 30 minutes and then diluted 
two-fold (1:20-1:40,960) in DMEM + 5% FBS.  An equal volume of 100 plaque-forming units 
(PFU)/0.1 mL of ZH501 RVFV diluted in DMEM + 5% FBS was added to the sera dilutions, 
making the final dilutions 1:40-1:81,920, two-fold.  The virus/serum mixtures were incubated at 
4oC overnight and then used to inoculate confluent monolayers of Vero E6 cells in duplicate on 
12-well plates.  The cells were incubated at 37oC and 5% CO2 for 1 hour with gentle mixing 
every 15 minutes.  The inoculate was removed completely from the wells and replaced with 
nutrient overlay (1X minimum essential medium, 2% FBS, 1% pen/strep, HEPES buffer, and 
0.8% SeaKem agarose).  The plates were incubated for 3 days, after which the cells were fixed 
with 37% formaldehyde for several hours in the biosafety cabinet.  The formaldehyde was 
drained and the agar overlay was removed before staining with crystal violet working solution 
for visualization of the plaques.    The neutralizing antibody titer was considered positive at the 
highest serum dilution that inhibited greater than 50% of the plaques as compared to the titration 
of the virus with no serum.   
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4.0  RESULTS 
4.1 AIM 1: TO DEVELOP METHODOLOGY FOR MEASURING ANTIBODY 
RESPONSES USING AN INDIRECT IGG ENZYME-LINKED IMMUNOSORBANT 
ASSAY (ELISA) AND PLAQUE REDUCTION NEUTRALIZATION TEST (PRNT50) 
FOR QUANTITATIVE DETERMINATION OF ANTIBODIES IN 3 STRAINS OF RATS 
AND 4 SPECIES OF NON-HUMAN PRIMATES EXPOSED TO AEROSOLIZED RIFT 
VALLEY FEVER VIRUS.   
Commercially-produced RVFV antibody detection kits, and even purified antigen for use 
in these tests, are publically unavailable for scientific purposes.  Due to the recent spread of 
RVFV into virgin territories and its potential for use as a bioweapon, a high-quality, sensitive, 
specific and safe assay is warranted for diagnostic and research use.  RVFV diagnosis is 
currently accomplished by several techniques, including virus isolation, antigen detection, 
nucleic acid amplification, and detection of specific antibodies.  Unfortunately, these methods 
tend to be time-consuming and expensive, making rapid diagnosis difficult.  Most endemic 
regions do not have the facilities and resources to safely handle the virus, putting laboratory 
workers at risk for infection79.  Several enzyme-linked immunosorbant assays (ELISAs) have 
been described, although most of these tests are based on reagents that are expensive and onerous 
to produce80.   
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Paweska et al. has previously described and validated methods for an indirect ELISA to 
measure the IgG response in exposed populations.  Using his methodology and a protocol 
received from USAMRIID (United States Army Medical Research Institute of Infectious 
Diseases, kind gift from D. Smith) as a guide, we have developed an indirect IgG ELISA using 
inactivated MP-12-infected lysate as a coating antigen.  The antigen is relatively quick, easy, and 
inexpensive to produce and can be generated in large quantities to ensure a standardized stock. 
To account for background and reduced specificity, a mock-infected lysate was used for 
comparison.  To determine the strength of the antibody response, we employed a sumOD 
approach that has been utilized in past studies and is accepted as a standard way of quantifying 
humoral immunity.  SumOD was calculated by measuring the absorbance of multiple serum 
dilutions in both mock- and MP-12-infected lysate-coated wells.  The average optical density 
from each mock-coated dilution was subtracted from the average optical density of the 
corresponding MP-12-coated dilution.  The differences of the dilutions were added together to 
obtain the sumOD value (Figure 1).  Samples were considered positive for IgG if the sumOD 
value was greater than the average of the control sumOD plus 3 standard deviations.  The control 
sumODs were calculated using mock-infected control animal samples and were species- and 
strain-specific for comparison to infected animals.  The sumOD provides a more accurate 
representation of antibody response than a single dilution.   
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1 2 3 4 5 6 7 8 9 10 11 12
A 0.121 0.055 0.681 0.751 0.904 0.862 0.077 0.067 0.09 0.081 0.083 0.082
B 0.048 0.048 0.65 0.658 0.785 0.771 0.091 0.049 0.11 0.084 0.075 0.066
C 0.047 0.05 0.486 0.44 0.476 0.506 0.055 0.057 0.072 0.101 0.182 0.09
D 0.052 0.071 0.26 0.255 0.308 0.294 0.078 0.087 0.11 0.079 0.062 0.038
E 0.886 1.137 0.903 0.878 0.132 0.132 0.149 0.235 0.184 0.208 0.163 0.154
F 1.011 1.135 0.941 0.879 0.176 0.169 0.178 0.181 0.162 0.172 0.163 0.154
G 0.678 0.722 0.655 0.669 0.182 0.227 0.215 0.188 0.188 0.188 0.186 0.194
H 0.492 0.455 0.438 0.435 0.175 0.179 0.172 0.183 0.187 0.174 0.184 0.179
MP12 average Mock average 
R3A1 R3F1 R3F2 R3G1 R3G2 R3A1 R3F1 R3F2 R3G1 R3G2
1:100 0.088 0.716 0.883 1.0115 0.8905 1:100 0.072 0.0855 0.0825 0.192 0.196
1:400 0.048 0.654 0.778 1.073 0.91 1:400 0.07 0.097 0.0705 0.1795 0.167
1:1600 0.0485 0.463 0.491 0.7 0.662 1:1600 0.056 0.0865 0.136 0.2015 0.188
1:6400 0.0615 0.2575 0.301 0.4735 0.4365 1:6400 0.0825 0.0945 0.05 0.1775 0.1805
SumOD (MP12 sum of dilutions - Mock sum of dilutions) MP12 average - Mock average
R3A1 R3F1 R3F2 R3G1 R3G2 R3A1 R3F1 R3F2 R3G1 R3G2
1:100-
1:6400 -0.0345 1.727 2.114 2.5075 2.1675 1:100 0.016 0.6305 0.8005 0.8195 0.6945
1:400 -0.022 0.557 0.7075 0.8935 0.743
MP12 blank average Mock blank average 1:1600 -0.0075 0.3765 0.355 0.4985 0.474
0.19075 0.18575 1:6400 -0.021 0.163 0.251 0.296 0.256
Figure 1: 96 well plate set-up and sumOD calculations. 
Schematic showing how each plate was arranged, using 5 serum dilution samples and blanks (top).  Depiction of the 
sumOD calculations (bottom).  Areas shaded blue represent a mock-infected control animal. 
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The gold standard for RVFV diagnosis is a plaque reduction neutralization test (PRNT). 
Although the test is lengthy and requires 5 days for completion, it is highly accurate, can be used 
for any species, and can validate the results of other assays81.   
Several investigators have previously described protocols for a RVFV PRNT50 assay.  
Based on these methods and guidance from USAMRIID, we have optimized a PRNT50 assay for 
use with ZH501 and our rat and non-human primate serum samples (see Materials and Methods 
section).  This assay was used for validation purposes for our IgG ELISA, as well as to 
determine the role of neutralizing antibodies in RVFV respiratory infection of our animal 
models.  During infection with RVFV, neutralizing antibodies are raised against the viral 
glycoproteins and are thought to mediate protection of uninfected cells82.  There is a dearth of 
information regarding humoral responses to RVFV and further investigation is warranted to 
determine the role that neutralizing antibodies play in host immunity.    
Using mock-infected control animals as antibody-negative samples and known ZH501-
infected animals (based off of fever response and weight loss data, not shown) as antibody-
positive samples, we were able to conclude that our indirect IgG ELISA and PRNT50 assays are 
sensitive and specific for RVFV antibodies in both rats and non-human primates.   
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4.2 AIM 2: TO CHARACTERIZE THE STRENGTH AND TIMING OF THE TOTAL 
IGG ANTIBODY RESPONSE IN THE 3 RAT STRAINS EXPOSED TO AEROSOLIZED 
RVFV.    
To establish the role that total IgG antibodies play in clinical disease outcome in rats 
exposed to aerosolized RVFV, we analyzed serum samples collected from Wistar-Furth, ACI, 
and Lewis rats used in median lethal dose and serial sacrifice studies.  Median lethal dose studies 
were conducted to determine the LD50 for aerosolized RVFV, as well as to confirm the disease 
outcome (hepatic disease, meningoencephilitis, and febrile illness for Wistar-Furth, ACI, and 
Lewis rats, respectively) for each rat strain, based off of a historical subcutaneous inoculation 
study by Peters and Sloan.  Aerosol exposure to RVFV resulted in acute hepatitis for Wistar-
Furth rats and neurological disease for ACI rats, as expected.  Surprisingly, respiratory exposure 
of Lewis rats, which were shown to develop only febrile disease to s.c. infection, mimicked the 
outcome seen in ACI rats, leading to fatal encephalitis.  This suggests that the route of 
inoculation is a critical determinant of disease outcome, and could result in grave consequences 
to exposed populations if RVFV were to be weaponized.  The median lethal dose was 
determined to be 2 PFU, 123 PFU, and 112 PFU for Wistar-Furth, ACI, and Lewis rats, 
respectively (Figure 2).  Aerosolization with RVFV caused 100% mortality at much lower doses 
than was seen through s.c. infection (Table 1).    
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The clinical outcome results of RVFV infection is influenced by route of administration and rat strain.
To determine the robustness of the IgG antibody response to aerosol RVFV infection, 
serum samples taken at necropsy from the LD50 studies were assayed using our indirect IgG 
ELISA (Figure 2).  For hepatitis-sensitive Wistar-Furth rats, doses above 5 PFU resulted in 
100% mortality with sumODs for deceased rats being slightly lower than the sumODs of the 
survivors at doses of 0.4 and 5 PFU.   Wistar-Furth rats were found to be highly susceptible to 
aerosolized RVFV, with even the lowest dose of less than 1 PFU resulting in fatal hepatic 
necrosis for one animal.  ACI rats, which exhibit the delayed-onset encephalitis seen in humans, 
were somewhat more resistant to fatal infection.  Survival was observed for all dose groups 
except at the highest dose of 3,900 PFU, although mortality occurred at as low as 20 PFU. 
Surviving ACI rats displayed a stronger IgG response than the Wistar-Furth and Lewis rats, with 
Table 1: Comparison of disease outcome of different rat strains after subcutaneous or aerosol exposure to 
RVFV 
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the average sumOD becoming greater as the presented dose increased.  Lewis rats, previously 
shown to control s.c. infection, were found to be vulnerable to neurological disease when 
subjected to RVFV aerosolization.  Complete seroconversion was seen for surviving rats that 
received doses of 1.5 or 30 PFU, but not all rats that succumbed to infection mounted an IgG 
response.  
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 Survivors  Deceased 
Presented 
Dose
# of IgG+ 
rats
Total # of 
rats
% of IgG+ 
rats
SumOD 
Average
# of IgG+ 
rats
Total # of 
rats
% of IgG+ 
rats
SumOD 
Average
Avg. # days 
to death
Control 0 6 0% -0.033 - - - - -
0.4 PFU 2 4 50% 0.473 0 1 0% 0.112 8
5 PFU 1 1 100% 0.881 1 1 100% 0.348 8
40 PFU - - - - NS NS NS NS NS
240 PFU - - - - 0 3 0% 0.093 3.67
 Survivors  Deceased 
Presented 
Dose
# of IgG+ 
rats
Total # of 
rats
% of IgG+ 
rats
SumOD 
Average
# of IgG+ 
rats
Total # of 
rats
% of IgG+ 
rats
SumOD 
Average
Avg. # days 
to death
Control 0 4 0% -0.002 - - - - -
0.4 PFU 0 4 0% -0.003 - - - - -
2 PFU 5 5 100% 2.169 - - - - -
20 PFU 5 5 100% 2.918 2 2 100% 1.373 13
250 PFU 4 4 100% 3.722 2 2 100% 0.312 8
3900 PFU - - - - NS NS NS NS NS
27 
 Survivors  Deceased 
Presented 
Dose
# of IgG+ 
rats
Total # of 
rats
% of IgG+ 
rats
SumOD 
Average
# of IgG+ 
rats
Total # of 
rats
% of IgG+ 
rats
SumOD 
Average
Avg. # days 
to death
Control 0 5 0% 0.055 - - - - -
1.5 PFU 5 5 100% 1.790 - - - - -
30 PFU 3 3 100% 1.586 - - - - -
350 PFU NS NS NS NS 1 2 50% 0.136 7.5
4400 PFU - - - - 4 5 80% 0.234 7
Figure 2: Determination of LD50 and IgG antibody response in surviving and deceased rat strains following 
aerosol exposure to RVFV at various presented doses. 
Cohorts of female Wistar-Furth, ACI, and Lewis rats (8-10 weeks old) were challenged with increasing doses of 
aerosolized RVFV or sham inoculation to determine the median lethal dose (LD50).  The rats were monitored daily 
after exposure for clinical signs, increased temperature, and weight loss.  Rats found moribund were euthanized.  (A) 
Wistar-Furth, (B) ACI, and (C) Lewis rats.  NS, no serum available for analysis.  It should be noted that the total 
number of rats listed for each dose does not always sum to the total number of rats exposed to that dose due to 
unavailability of serum.  
For our median lethal dose studies, we have shown that clinical disease outcome and IgG 
antibody response is dependent on the selection of inbred rat strain.  Surviving rats demonstrated 
complete seroconversion at presented doses above 1 PFU with a higher dose typically correlating 
with a faster time to death than seen with a lower dose.  SumODs, on average, increased as the 
presented dose of RVFV increased for survivors. 
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Figure 3: Wistar-Furth rats do not mount a detectable IgG antibody response after respiratory infection with 
RVFV. 
Experimental animals received an aerosolized dose of 400 PFU of ZH501, with control animals receiving a sham 
aerosol inoculation.  Each point represents the IgG sumOD of an individual rat at sacrifice.  Control animals were 
used to determine the cut-off value, which is indicated by the dotted line.  Animals were considered positive for IgG 
if the sumOD was greater than the value of the cut-off.   
After comparing IgG titers between surviving and deceased rats, we wanted to determine 
the emergence and strength of the IgG response in serial sacrifice studies with the 3 strains of 
rats.  To elucidate the timing of the total IgG antibody response, we again utilized our indirect 
ELISA with a sumOD approach.  Since the average time to death was 4 days for Wistar-Furth 
rats, all animals were presented with a lethal dose of 400 PFU with cohorts sacrificed on days 1, 
2, and 3 post-infection.  None of the sacrificed animals displayed a detectable IgG response to 
infection (Figure 3).  ACI rats were determined to survive an average of 6 days after aerosol 
infection.  Therefore, cohorts of rats were presented with a fatal dose of 7,500 PFU and were 
sacrificed on days 1 through 7 post-infection.  Complete seroconversion of a cohort appeared on 
day 6 post-infection (Figure 4), indicating that B cell activation and efficient isotype switching 
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has occurred by this point.  The highest sumODs were seen on day 7 post-infection.  Lewis rats, 
which exhibited a similar clinical disease course as ACI rats in the median lethal dose study, 
averaged 7 days to death post-infection.  Lewis rats were exposed to a deadly dose of 30,000 
PFU of RVFV and sacrificed on days 1 through 7.  Akin to the ACI rats, Lewis rats also showed 
complete seroconversion by day 6 post-infection, with the most robust IgG response detected on 
day 7 post-infection (Figure 5).   
Figure 4: ACI rats develop an IgG antibody response by day 6 post-infection when challenged with 
aerosolized RVFV. 
ACI rats were presented with a dose of 7,500 PFU of ZH501 or were sham-inoculated (control animals).  Complete 
IgG seroconversion occurred by day 6 post-infection.  Each point is indicative of the IgG sumOD of a single rat at 
the time of sacrifice.  The dotted line represents the cut-off value, which was determined by control animal sumODs.  
Rats were deemed positive for IgG if the sumOD exceeded the value of the cut-off.   
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In conclusion for the serial sacrifice studies, Wistar-Furth rats never mounted a detectable 
IgG response and likely succumb to infection prior to class switching.  ACI and Lewis rats 
showed total seroconversion by day 6 post-infection, with day 7 showing an even greater 
antibody response. 
Figure 5: Lewis rats display a similar clinical outcome and IgG antibody response in comparison to ACI rats 
after aerosol exposure to RVFV. 
Lewis rats were delivered a dose of 30,000 PFU of ZH501 by aerosol inoculation. Control rats were sham-
inoculated.  IgG seroconversion resulted by day 6 post-infection, with the highest average sumODs seen on day 7. 
Each point denotes the sumOD for an individual animal.  The cut-off value, determined by the control rat sumODs, 
is represented by the dotted line.  Animals were considered IgG-positive if the sumOD surpassed the cut-off value.   
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4.3 AIM 3:  TO CHARACTERIZE THE STRENGTH AND TIMING OF BOTH THE 
TOTAL IGG AND NEUTRALIZING ANTIBODY RESPONSES IN 4 SPECIES OF NON-
HUMAN PRIMATE EXPOSED TO AEROSOLIZED RVFV.   
A susceptible non-human primate (NHP) model for RVFV aerosol infection has not been 
established for use in biomedical research83.  Multiple NHP species from around the world have 
been evaluated for susceptibility to RVFV through various exposure routes including 
subcutaneous, intravenous, intraperitoneal, intranasal, and aerosol84.  Viremia, fever response, 
and leukopenia are frequently reported in these studies, but most species are resistant to 
developing severe clinical disease85.  The rhesus macaque is considered to be an appropriate 
model to mimic general human infection after i.v. challenge with ZH501.  Most animals develop 
a mild febrile disease, with a lesser proportion progressing to a more critical outcome.  As rhesus 
macaques are only moderately susceptible to infection, they do not provide an ideal model when 
testing the efficacy of vaccines and therapeutics.  Furthermore, i.v. exposure to RVFV is not a 
natural route of infection, since mosquitoes transmit virus extravascularly86.   
Although non-human primates do not seem to produce a uniform response to RVFV 
inoculation, previous studies have suggested that the respiratory route of infection may be 
slightly more pathogenic87.  To determine which NHP species could best mimic the 
manifestations seen in severe human disease after respiratory challenge, rhesus macaques, 
cynomolgus macaques, and African Green monkeys (AGMs) were exposed to high doses (5 
log10 PFU/ml) of aerosolized ZH501 in duplicate.  A pre-infection blood draw confirmed that the 
animals were RVFV-naïve by our indirect IgG ELISA and PRNT assays.  The NHPs were 
monitored daily for signs of clinical disease, and implanted telemetry devices were used to 
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measure physiological responses to infection.  Blood samples were taken at the midpoint of the 
study, with euthanasia and necropsy occurring for the surviving animals at 28 days post-
infection.  All animals survived to the end of the study, with the exception of an African Green 
monkey succumbing to neurological disease at day 11 post-infection.   
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Figure 6: The total IgG responses over time of 3 species of non-human primates exposed to aerosolized 
RVFV. 
Cynomolgus macaques, Rhesus macaques, and African Green monkeys were challenged with high doses of 
aerosolized ZH501.  Blood samples were taken prior to infection, at the midpoint of the study, and at 
necropsy.  Individua l animals are represented by a single color per graph.  Blue and green points indicate the first 2 
animals of a species infected via aerosol.  Stars represent animals that succumbed to infection.  The cut-off values, 
indicated by the dotted line, were determined by the sumODs from the pre-infection bleed.  Animals were 
considered IgG-positive if the sumOD value exceeded that of the cut-off. 
34 
Since the AGM species showed promise of a susceptible model, a cohort of an additional 
2 AGMs was challenged with comparable doses of aerosolized RVFV.  Both of these animals 
developed symptoms of the same neurological disease seen in the AGM with the fatal infection, 
and ultimately were euthanized 11 days post-exposure.   This species will be further evaluated in 
future studies for their likelihood to be used as a realistic model of severe neurological infection.   
Blood samples taken at pre-infection, midpoint, and necropsy were assayed using our indirect 
ELISA to determine the strength of the IgG response to respiratory exposure to RVFV (Figure 
6).  All surviving NHPs showed a robust antibody response at necropsy, with the general trend of 
an increasing sumOD at each subsequent time point after infection.  Not all surviving animals 
developed a strong IgG response by the midpoint of the study, but extremely high neutralizing 
antibody titers were detected in both the midpoint and necropsy samples by PRNT50 for all NHPs 
(Table 2).  The AGM that developed the fatal infection did not seroconvert to IgG, but did mount 
a vigorous neutralizing antibody response with a titer of 1:5,120.  All surviving animals, 
however, had neutralizing titers greater than 1:81,920.   
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Table 2: Overview of non-human primate aerosol exposure study 
Two animals of different non-human primate species (cynomolgus macaques, rhesus macaques, and African Green 
monkeys) were exposed to aerosolized RVFV after a pre-infection bleed.  The primates were monitored daily for 
signs of illness and weight loss, and implanted telemetry devices recorded temperature changes.  Blood was drawn 
at the midpoint at the study, and taken again at necropsy.  Serum samples were used in indirect ELISA assays and 
plaque reduction neutralization tests to determine the total IgG response and neutralizing antibody titers, 
respectively, at midpoint and necropsy.  Text color refers to results in Figure 5. 
Recently, a study reported that the common marmoset was a more useful model of severe 
RVFV infection than other NHP species88.  The marmosets in this study were challenged via i.v., 
s.c., or i.n.  exposure routes, and it was discovered that animals inoculated intranasally developed
the highest rates of morbidity and mortality.  To determine if marmosets could be a useful model 
for aerosol infection with RVFV, a cohort of 2 animals were exposed to aerosolized RVFV.  
After infection, telemetry implants monitored physiological parameters, and the animals were 
evaluated daily for signs of disease.  Ten days after aerosol exposure, both marmosets began 
showing neurological signs and were thereafter euthanized and necropsied.    
Pre-infection           Midpoint    Necropsy 
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Figure 7: Comparison of sumOD values at necropsy in surviving and deceased marmosets. 
A total of 8 common marmosets were aerosol-challenged with RVFV.  Four animals displayed neurological 
symptoms at days 9 and 10 and were euthanized.  The results obtained from the first 2 animals used in the study are 
depicted by blue and green dots. 
To establish if the results were reproducible and the species was susceptible to respiratory 
RVFV exposure, we infected 6 additional marmosets by aerosol at increasing doses of log10.  
Two marmosets developed lethal encephalitis on days 9 and 10, respectively, and were 
euthanized.  The 4 remaining marmosets survived until the end of the study.  Samples taken at 
necropsy were used to determine sumODs and neutralizing antibody titers using our developed 
IgG ELISA and PRNT assays (Figure 7, Table 3).  Surviving animals had markedly higher 
average sumODs than the deceased animals, with all animals displaying extremely high 
neutralizing antibody titers.  Although the animal that succumbed on day 9 post-infection had a 
neutralizing titer of 1:40,960, it did not prove effective in conferring protection against disease.   
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Table 3: Overview of the humoral immune responses seen in marmosets after respiratory infection with 
ZH501 
Eight common marmosets were aerosol-challenged with varying doses of RVFV.  Results are divided by those 
surviving infection, and those that did not.   Blue and green text refers to the first 2 animals challenged in the study. 
NS, no serum available for analysis.   
Survivors   Deceased 
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5.0  DISCUSSION 
Rift Valley fever virus is an important zoonotic arbovirus, responsible for causing severe 
outbreaks of disease in livestock and humans in Africa and the Arabian Peninsula.  Due to 
certain viral characteristics such as ability to be aerosolized, availability of competent 
transmission vectors, and globalization of travel and trade, RVFV has high potential to be 
introduced intentionally or accidently to virgin territories, leading to dramatic socio-economic 
consequences.  Since RVFV is a category A select agent with concern about its potential use as 
an aerosol, understanding the pathogenesis of inhalational disease is a top priority for the 
development of medical countermeasures and defense against potential biological warfare.   
Cases of Rift Valley Fever resulting from inhalational exposure have been reported in 
laboratory settings, but due to the lack of public health infrastructure in most endemic countries, 
few cases of respiratory RVFV infection have been confirmed during outbreaks.  It is unknown 
whether the route of exposure determines or influences the outcome of human clinical disease. 
Because human trials are unethical and likely implausible during epidemics, well-defined animal 
models must be developed for research purposes.   
Defining an animal model of includes characterizing the host immune response to the 
delivered pathogen.  The humoral response plays an important role in clearing infections and 
affecting the clinical course of the disease.  Determining what role the antibody response plays in 
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protecting against fatal infection will give insight into possible mechanisms for developing 
vaccines and therapeutics.  There is worry that aerosolized RVFV will be used as a biological 
weapon, which dictates the urgent need for countermeasures. 
Based on the rat model described by Peters and Sloan in 1982, s.c. infection of Wistar-
Furth, ACI, and Lewis rats with the ZH501 strain of RVFV resulted in necrotic hepatitis, 
meningoencephilitis, and a mild febrile illness, respectively.  As each inbred rat strain modeled 
one of the distinct outcomes seen in human RVFV infection, it was suggested that host genetic 
susceptibility determined the clinical course of disease89.  In a medial lethal dose study, we have 
shown that exposure to low or moderate doses of aerosolized RVFV results in acute hepatic 
disease for Wistar-Furth rats and neurological disease for both ACI and Lewis rats.   
To investigate the role of the humoral response in shaping disease outcome, rates of IgG 
seroconversion and sumOD values were compared between the surviving and deceased rats at 
corresponding presented doses.  Aerosol exposure to RVFV causes higher mortality rates and 
faster time to death in inbred rats compared to subcutaneous infection, even at low to moderate 
doses.  For all rats, a presented aerosol dose above 1 PFU resulted in complete seroconversion 
for surviving animals. This suggests that inhalation of a single virion can lead to infection and 
that a population’s exposure to even a small amount of aerosolized RVFV could have dire 
repercussions.   
Wistar-Furth rats, which quickly progressed to acute hepatitis after aerosol infection, 
reached 100% mortality at extremely low doses of ZH501.  When comparing average sumOD 
values between surviving and deceased rats at the two lowest doses, survivors had at least twice 
the average sumOD than deceased rats that received the same dose.  The average time to death 
for the deceased rats was 8 days, which should have allowed sufficient time for the rats to 
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seroconvert to IgG.  Therefore, it is possible that the higher IgG antibody titers seen for the 
survivors conferred protection against fatal disease.  Overall, Wistar-Furth rats had lower 
sumOD averages than the other inbred rat strains.   
Several factors may have positively or negatively affected the calculated average sumOD 
for the Wistar-Furth rats.  Of the surviving rats that were presented a dose of 0.4 PFU, only half 
of the exposed seroconverted, indicating that some rats may not have been infected by such a 
low dose.  Due to unavailability of serum, not every rat was included in the sumOD average, and 
several averages were determined by only one animal, which would not be representative of the 
cohort.  Since Wistar-Furth rats fully succumbed to the highest doses of RVFV, a low presented 
dose may not have had the ability to elicit a strong IgG response, with higher sumODs being 
attainable by exposure to median doses of virus.  The fastest time to death and lowest average 
sumOD were seen in rats that received an inoculation of the highest dose.  Because rats were 
euthanized at days 3 and 4 at this dose, it is likely that they did not have sufficient time to mount 
an IgG response.  We demonstrated that these rats do not mount a detectable IgG response by 
day 3 post-infection.  The Wistar-Furth model of aerosol challenge faithfully represents the 
severity of RVFV-induced hepatitis in humans.  As infected hosts do not have adequate time to 
mount a specific and robust antibody response before fatal hepatic disease sets in, demand for an 
immunogenic vaccine to prevent infection is more apparent than the deficit of post-exposure 
treatment for this clinical outcome. 
A proportion of ACI rats were shown to develop neurological disease after s.c. infection 
with RVFV, mimicking the delayed-onset encephalitis recognized in severe human cases.  After 
an aerosol challenge to determine the median lethal dose, exposed rats displayed the same 
neurologic symptoms as seen with s.c. infection.  Similar to Wistar-Furth rats, ACI rats 
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succumbed faster and at lower doses than required by s.c. inoculation.  Surviving ACI rats 
yielding the highest average sumODs seen in the study.   
Rats exposed to median doses of RVFV resulted in both survival and death.  Of those that 
succumbed, the average time to death was 13 days post-infection.  Even at nearly two weeks 
after exposure, the IgG response for deceased rats was less than half of that of the survivors, 
based on average sumOD.  As demonstrated by the Wistar-Furth and Lewis rats, the sumOD 
average of the deceased ACI rats infected with moderate doses should have been robust enough 
to protect against fatal disease.  Because antibodies are too large to cross the blood-brain 
barrier90, it is possible that the IgG response could have protected against death if the virus did 
not breach the CNS.  There may also be a certain threshold that antibody titers must cross before 
protection can occur.   
In surviving rats challenged with higher doses of RVFV, average sumODs were nearly 12 
times higher than the sumODs of the deceased at a comparable dose.  We observed the 
emergence of the IgG antibody response at day 6 post-infection for this strain, albeit at weak 
levels.  Although the deceased rats fully seroconverted by day 8 post-infection, the average 
sumODs remainined low, suggesting that a robust IgG response potentially lessens disease 
severity and decrease mortality rates. 
When inoculated s.c. with RVFV, Lewis rats proved able to control the virus and resist 
disease.  Interestingly, Lewis rats were unexpectedly susceptible to respiratory RVFV infection 
and displayed neurological symptoms similar to those exhibited by ACI rats.  As the Lewis rat 
data conflicted with prior reports, a cohort of rats was administered a comparable s.c. dose of 
virus.  All rats survived s.c. infection without showing signs of illness (data not shown). This 
finding suggests that the route of infection can influence clinical outcome, and that aerosol 
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exposure to RVFV may be more burdensome than originally conceived from a biodefense 
standpoint.  A possible explanation for the encephalitis seen in Lewis rats is that the virus 
infiltrates the central nervous system (CNS) through the olfactory bulb, but mechanisms for the 
discrepancy between the route of infection and clinical outcome seen in the Lewis strain warrants 
further investigation.   
Even at the highest presented doses of RVFV, complete seroconversion of a dose cohort 
did not occur by day 7 post-infection, with several rats deemed IgG-negative.  Our Lewis serial 
sacrifice data indicates that the IgG immune response appears 6 days post-challenge, with 
sumODs increasing slightly on day 7, analogous to ACI rats.  The lack of seroconversion could 
indicate a delayed humoral response to aerosol infection and antagonism of the innate immunity 
in this rat strain. 
Our rat studies have shown that RVFV challenge via aerosol results in higher morbidity 
and mortality when compared to other inoculation routes.  At presented doses above 1 PFU, total 
IgG seroconversion occurred for all surviving rats, indicating extremely high infectivity of 
aerosolized RVFV.  These characteristics of respiratory infection make aerosolized RVFV a 
serious threat from a military perspective, and further justify the pressing need for vaccine and 
therapeutic development.  Selection of inbred rat strain significantly impacts the disease course, 
although outcome can vary based upon the route of infection, as demonstrated by our Lewis rat 
studies.    
The varied IgG responses seen between the different rat strains and how they correlate 
with presented dose could create obstacles for the development of vaccines, since immunization 
would need to protect against all clinical forms of inhalational disease.  For example, protective 
antibodies cannot cross the blood-brain barrier, so the mechanism for protection against 
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neurological disease would need to be directed at eliciting both cell-mediated and humoral 
responses.  As hepatic disease is characterized by localized regions of necrosis, a vaccine 
eliciting a powerful killer T-cell response could exacerbate pathogenicity.  Since we are 
investigating inoculation with RVFV at lung (and possibly olfactory) mucosa, prophylaxis 
geared toward evoking a strongly neutralizing IgA response could be most effective in 
preventing all forms of clinical disease. 
Non-human primates are commonly considered to be one of the most realistic models to 
study the pathogenesis of human disease due to shared similarities in presentation of clinical 
illness.  Unlike inbred rats, NHPs have shown inconsistencies in disease outcome after infection 
with RVFV.  While most NHPs do develop viremia after challenge, they often remain 
asymptomatic91.  As the ultimate goal is to develop and test medical countermeasures for severe 
disease, a highly susceptible and well-defined NHP model is desired.  Several different Old 
World and New World species have been infected with RVFV with unpromising results.  
Although the rhesus macaque mimics the human spectrum of disease with less than 20% of those 
exposed progressing to critical outcomes after i.v. infection, large cohorts of animals would be 
needed and the studies would be extremely costly, as well as unnatural.  Few NHP studies have 
utilized aerosolized RVFV and data is lacking for this inoculation route.   
Rhesus macaques, cynomolgus macaques, and African Green monkeys were respiratory-
challenged with high doses of RVFV.  The rhesus and cynomolgus macaques failed to show any 
clinical signs of disease, despite exhibiting a biphasic fever response (data not shown).  Eleven 
days post-infection, one AGM began displaying symptoms of neurological disease and was 
euthanized.  The moribund animal had previously developed an infection at the site of the 
telemetry implant.  To dispel the possibility that secondary infection contributed to the AGM’s 
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fatal disease, an additional 2 AGMs were aerosol-challenged and were euthanized on day 11 
post-infection after showing symptoms of encephalitis.   
Based on pre-infection, intermediate, and necropsy bleeds from the 3 NHP species, we 
determined that the sumOD increased at each time point for survivors.  Seroconversion occurred 
for some of the NHPs by the midpoint bleed, but no correlation was observed between survival 
and presence of IgG antibodies at midpoint.   
Neutralizing antibodies are thought to be protective against RVFV infection, and could 
possibly have an effect on clinical outcome92.  By the midpoint of the study, all NHPs had 
exceptionally high neutralizing antibody titers, but despite the titers, the antibodies did not prove 
to be neuroprotective for the deceased AGMs.   This situation, like that of the encephalitic rats, 
may also illustrate the effects of antibodies failing to cross the blood-brain barrier.  Determining 
if AGMs are an appropriate model for human neurological disease will be in evaluated in future 
studies. 
Neutralizing antibodies can exist in any combination of the 5 antibody isotypes.  Since 
the IgG sumODs of the euthanized NHPs were very low, it is possible that another isotype, such 
as IgM, could constitute the majority of the neutralizing titers.  Although this isotype constitutes 
a very small percentage of serum antibodies, IgA antibodies may play an important role in 
halting the progression of disease resulting from mucosal infection.  The importance of 
individual antibody isotypes must be further examined, and may include measurement of serum 
IgM levels and determination of IgA titers in bronchoalveolar lavage (BAL) fluid.   
Historical studies have indicated that aerosol challenge of NHPs may be marginally more 
pathogenic than other inoculation routes and a recent study from USAMRIID found common 
marmosets to be susceptible to intranasal infection.  To this end, we challenged a pair of 
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marmosets through inhalational exposure to ZH501.  At 10 days post-infection, both marmosets 
were discovered moribund with encephilitis and were subsequently euthanized.  Six additional 
marmosets were added to the study and received low, moderate, and high doses of RVFV.  Two 
marmosets displaying neurologic symptoms were euthanized on days 9 and 10 post-challenge, 
with the remaining monkeys surviving to the end of the study.   
Serum samples taken from each animal at necropsy revealed that surviving marmosets 
had high average IgG sumODs and exceptionally potent neutralizing titers.  Average sumODs 
for deceased animals were barely detectable, but neutralizing antibody titers were as strong as 
the titers for survivors.  As this phenomenon was recognized across multiple NHP species and rat 
strains after respiratory exposure to RVFV, continued exploration of the humoral immune 
response and determining the role, if any, that neutralizing antibodies play in neurologic disease 
progression are necessary to gain insight into NHP pathogenesis.  
A possibility to address the discordance between neutralizing and IgG antibodies lays in 
the target of the antibodies.  As previously described, our PRNT50 assay measures the 
neutralizing antibodies present in serum, which are directed at the viral glycoproteins.  The 
neutralizing antibodies bind to the glycoproteins and therefore prohibit infection from occurring.  
IgG antibody titers were quantitated with our IgG ELISA using whole lysate to coat the plates.  
Because whole lysate is used in place of a purified protein in our assay, detectable IgG 
antibodies can be directed at any viral protein, including glycoproteins, the N protein, NSs, and 
others.  Neutralizing antibodies did not seem to play an important role in limiting disease 
progression, indicating that antibodies to non-structural proteins (such as the immunodominant N 
protein) may confer greater protection against disease.  Further investigation is needed to 
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elucidate the mechanisms and roles of antibodies targeted to structural and non-structural 
proteins. 
Examining innate immune factors, such as cytokines and interferon, and adaptive 
components, like CD8+ T cells, will further our understanding of the complex relationship 
between aerosol infection and host immunity, and will contribute to the development of well-
defined rat and NHP animal models.  Considering that the introduction of RVFV to naïve regions 
is a genuine possibility, understanding the immunology of the disease is imperative for the 
development of efficacious vaccines and effective treatments.  A greater scope of knowledge will 
hopefully provide insight to the underlying mechanisms of disease progression, viral or host 
characteristics responsible for triggering severe outcomes in certain individuals, and the means 
by which clinical disease can occur in the presence of high neutralizing antibody titers.   
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